[{"orgOrder":0,"company":"Medicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tirofiban","moa":"||Integrin-alpha-2b\/beta-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Medicure","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medicure \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Medicure \/ Inapplicable"},{"orgOrder":0,"company":"Medicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tirofiban","moa":"||Integrin-alpha-2b\/beta-3","graph1":"Hematology","graph2":"Phase II","graph3":"Medicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medicure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicure \/ Inapplicable"},{"orgOrder":0,"company":"Medicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pyridoxal Phosphate","moa":"Purinergic receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Medicure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medicure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Medicure \/ Inapplicable"},{"orgOrder":0,"company":"Medicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pyridoxal Phosphate","moa":"Purinergic receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Medicure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medicure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Medicure \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Medicure

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : MC-1 (pyridoxal phosphate) is a naturally occuring purinergic receptor antagonist, which is being evaluated for the treatment of Pyridox(am)Ine 5'-Phosphate Oxidase (PNPO) Deficiency.

                          Product Name : MC-1

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 23, 2024

                          Lead Product(s) : Pyridoxal Phosphate

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : FDA provides complete approval to enroll patients in its pivotal clinical trial to evaluate "MC-1" (a naturally occurring metabolite of pyridoxine) for treatment of a rare pediatric disease called pyridox(am)ine 5′-phosphate oxidase deficiency.

                          Product Name : MC-1

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 23, 2023

                          Lead Product(s) : Pyridoxal Phosphate

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : Notably, a non-randomized, case-controlled, investigator sponsored proof of concept study evaluating AGGRASTAT® in combination with standard of care in patients with severe COVID-19 and hypercoagulability found that enhanced platelet inhibition improves...

                          Product Name : Aggrastat

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 24, 2020

                          Lead Product(s) : Tirofiban,Aspirin,Clopidogrel

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : The FABOLUS-FASTER trial was designed to assess different regimens of intravenous platelet inhibitors, notably AGGRASTAT® (tirofiban hydrochloride) injection (an IV GP IIb/IIIa inhibitor) and cangrelor (an IV P2Y12 inhibitor) in the early phase of prima...

                          Product Name : Aggrastat

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 15, 2020

                          Lead Product(s) : Tirofiban,Prasugrel

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank